Home › Head and Neck Squamous Cell Carcinoma › NCT07219212
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Who can join
Ages 18 to 74 · All sexes
Full eligibility criteria
Inclusion criteria: * Pathologically (histologically or cytologically) proven diagnosis of HNSCC of the oral cavity, oropharynx (p16 negative), hypopharynx, or supraglottic larynx * Stage III, IVA or IVB according to the 8th Edition of the American Joint Committee on Cancer (AJCC) guidelines * A candidate for definitive concurrent chemoradiation therapy treatment as determined by investigator and per local guidelines * Participants must have at least 1 target lesion (primary tumor or involved lymph node) per RECIST v.1.1 * Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 Exclusion criteria: * Primary tumor originating in the nasopharynx, paranasal sinuses, salivary glands, thyroid gland, parathyroid gland, skin, or unknown primary site * Non-squamous histology * Stages 0, I, II, and IVC HNSCC, loco-regionally recurrent HNSCC, or synchronous second primary HNSCC (within 2 months) * Ineligible to receive platinum-based chemotherapy * Suspected or known allergies, hypersensitivity, or intolerance to JNJ-90301900 or its excipients
About the study
This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).
What is being tested
- JNJ-90301900 (drug)
- Cisplatin (drug)
- Intensity Modulated Radiation Therapy (IMRT) (radiation)
- Carboplatin (drug)
- Paclitaxel (drug)
Sponsor: Johnson & Johnson Enterprise Innovation Inc. · Participants: 45 · Started: Jan 26, 2026
Contact the study team
- Study Contact · Phone: 844-434-4210
Official record on ClinicalTrials.gov — NCT07219212
Locations in the U.S.
| Alabama | University of Alabama at Birmingham, Birmingham |
| California | City of Hope, Duarte |
| Florida | Mayo Clinic, Jacksonville Moffit Cancer center, Tampa |
| Georgia | Emory University, Atlanta |
| Massachusetts | Boston Medical Center, Boston |
| New York | Montefiore Medical Center, The Bronx |
| North Carolina | University of North Carolina at Chapel Hill, Chapel Hill |
| Pennsylvania | University of Pennsylvania, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.